JAMA study puts nicotine patches on par with Pfizer's Chantix; NICE gives final OK to a slate of cancer meds;

@FiercePharma: India and France committed to restart trade talks stalled on GVK row. More from FiercePharmaAsia | Follow @FiercePharma

@CarlyHFierce: ICYMI: J&J's new launches deliver, but overall sales fall short on hep C, strong dollar. Article | Follow @CarlyHFierce

> Pfizer's ($PFE) stop-smoking drug Chantix failed to beat nicotine patches in a 12-week open-label study published Tuesday by the Journal of the American Medical Association. Report

> U.K. cost watchdogs have given a final thumbs-up to AstraZeneca's ($AZN) Lynparza, Bayer's Xofigo, Astellas' Xtandi and Novartis' ($NVS) Farydak. Report

> The U.K.'s National Institute of Health and Care Excellence (NICE) remains unconvinced that Eli Lilly's ($LLY) stomach cancer med Cyramza is worth its price. Report

> According to J&J ($JNJ) CEO Alex Gorsky, the healthcare industry's investment in patient support programs and other value-added services is still in the "early innings." Report

> The Turkish government put through price increases on thousands of drugs. Report

> Cost regulators in the U.K. have approved routine use of Boehringer Ingelheim's Ofev as a treatment for some patients with idopathic pulmonary fibrosis (IPF).

Medical Device News

@FierceMedDev: J&J hints at 'bold steps' in device deals in 2016, details 5 device collaborations. Story | Follow @FierceMedDev

@EmilyWFierce: Big Pharma chalks up victory in Arizona Supreme Court over Rx safety warnings. ICYMI from FiercePharma | Follow @EmilyWFierce

> Israeli VC backed by Philips and Teva looking to invest $26M in promising med tech startups. Article

> Sony, Carlyle Group, KKR among bidders for Toshiba's imaging unit, expected to fetch $3B+. More

> Illumina finds match in Australian genomics company for transplant sequencing work. Report

Biotech News

@FierceBiotech: Researchers have isolated human monoclonal antibodies that target multiple strains of Ebola. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: $MNKD call on Feb. 3 gives investors a chance to ask a few questions. Release | Follow @JohnCFierce

> Langer-backed biotech reboots with $38M, new name and new cancer drug tech. More

> Novartis reshuffles its $9B R&D operation to save $1B a year. Report

> Backed by Novartis and Orbimed, Adicet joins immunotherapy crowd with $51M round. Article

Biotech Research News

> Researchers have isolated human monoclonal antibodies that target multiple strains of Ebola. Story

> Science team says they've taken another step toward a potential cure for diabetes. More

> UT Southwestern team says new liver cancer therapy shows promise in mice. Report

> New molecule targets cancer stem cells. Item

> UT Southwestern team IDs next-gen approach to fighting pancreatic cancer. Article

Vaccines News

> Takeda's Hib vaccine gets Japanese approval. More

> Case Western, Merck team spotlights vaccine response predictors. Report

> U.K., Gates pledge $4.3 billion to take malaria fight beyond vax. Story

> U.K. committee warns the country is unprepared for an epidemic. Item

> Zika outbreak triggers R&D attention from pharma, governments. Article

Pharma Marketing News

> Time to tap YouTube for talent? Cold remedy Zicam goes there in deal with singer Tyler Ward. More

> New brands, stepped-up spending drive big TV-ad outlay for diabetes in 2015. Story

> What do docs want? Face-to-face tablet meetings with reps. More

> Massachusetts AG threatens legal action against Gilead over pricey hep C meds. Item

> Shire's back on track with its dry-eye threat to Allergan's Restasis. Article

And Finally... Counterfeit drugs are a growing problem in Los Angeles. Report